Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sobi gets rights to Valeant's urea cycle disorder drug Ammonul

Executive Summary

In a three-year deal, Valeant Pharmaceuticals International Inc. licensed Swedish Orphan Biovitrum AB (Sobi) exclusive rights to sell and distribute Ammonul (sodium phenyl acetate and sodium benzoate) injection in Europe, the Middle East, and North Africa.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies